ALK and inflammatory myofibroblastic tumor: Although crizotinib is initially approved as a targeted therapy for NSCLC, a study focusing on inflammatory myofibroblastic tumors reported a partial response to it in a patient with ALK translocation, while there was no observed activity in another patient without the translocation[23].